Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

NCT06737354 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

nAMD

Interventions

GENETIC: IVB103 Injection（Low dose）
GENETIC: IVB103 Injection（Intermediate dose）
GENETIC: IVB103 Injection（High dose）

Sponsor

InnoVec Biotherapeutics Inc.

Collaborators

[object Object]